-
Product Insights
New![]()
Net Present Value Model: Clene Inc’s CNMAU-8
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eisai Co Ltd’s E-2814
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XEN-1101 in Tonic-Clonic (Grand Mal) Seizure
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XEN-1101 in Tonic-Clonic (Grand Mal) Seizure Drug Details: XEN-1101 (1OP-2198) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CNMAU-8 in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CNMAU-8 in Amyotrophic Lateral Sclerosis Drug Details: CNMAU-8 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CNMAU-8 in Parkinson’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CNMAU-8 in Parkinson's Disease Drug Details: CNMAU-8 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GRANITE-001 in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GRANITE-001 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: GRANITE-001 (Zvexneo) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CNMAU-8 in Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CNMAU-8 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details: CNMAU-8 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CNMAU-8 in Primary Progressive Multiple Sclerosis (PPMS)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CNMAU-8 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details: CNMAU-8 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Evorpacept in B-Cell Non-Hodgkin Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Evorpacept in B-Cell Non-Hodgkin Lymphoma Drug Details: Evorpacept is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Pembrolizumab+Vibostolimab) in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Pembrolizumab+Vibostolimab) in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Drug Details: MK-7684A is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.